Clinical parameters Good
n (145 %)
Poor
n (225 (60.8)
Total
n (370 100.0)
X2 Df P-value
Present BMI            
Underweight 3(16.7) 15(83.3) 18(100)      
Normal 94(45.2) 114(54.8) 208(100.0)      
Overweight 41(39.4) 63(60.6) 104(100) 14.88 3 0.0019
Obese 7(17.5) 33(82.5) 40(100.0)      
Total 145(39.2) 225(60.8) 370(100.0)      
Year of diagnosis            
<1years 6(24.0) 19(76.0) 25(100.0)      
1-5years 131(41.6) 184(58.4) 315(100.0) 5.15 2 0.0760
>5year 8(26.7) 22(73.3) 30(100.0)      
Total            
WHO  Clinical Stage of disease
Stage I 90(45.7) 107(54.3) 197(100.0)      
Stage II 52(35.9) 93(64.1) 145(100.0) 13.69 2 0.0011
Stage III 3(10.7) 25(89.3) 28(100.0)      
Year  HAART was commenced
<1years 9(33.3) 18(66.7) 27(100.0)      
1-5years 127(43.3) 166(56.7) 293(100.0)      
>5year 4(16.0) 21(84.0) 25(100.0) 7.78 2 0.0204
Total 140(40.6) 205(59.4) 345(100.0)      
HAART
alluvia/truvada 0(0.0) 2(100.0) 2(100.0)      
Combipak 99(38.8) 156(61.2) 255(100.0)      
truv/nvp 29(39.2) 45(60.8) 74(100.0)      
Truvada/EFV 8(66.7) 4(33.3) 12(100.0)      
Zdv, 3TC,EFV 0(0.0) 2(100.0) 2(100.0) 6.5006 5 0.2605
yet to start 9(36.0) 16(64.0) 25(100.0)      
Total 145(39.2) 225(60.8) 370(100.0)      
PRESENT CD4
<200
8(9.8) 74(90.2) 82(100.2)      
200-349 28(31.1) 62(68.9) 90(100.0)      
350-499 48(51.6) 45(48.4) 93(100.0) 22.21 2 0.00002
≥500 61(58.1) 44(41.9) 105(100.0)      
Total 145(39.2) 225(60.8) 370(100.0)      
Table 4: Clinical Parameters of the Respondents with Sexual Dysfunction Compared with those without Sexual Dysfunction.
Goto home»